Breaking News Instant updates and real-time market news.

ALDR

Alder Biopharmaceuticals

$12.23

-0.21 (-1.69%)

16:39
05/02/19
05/02
16:39
05/02/19
16:39

Alder Biopharmaceuticals reports Q1 EPS ($1.63), consensus ($1.03)

As of March 31, Alder had $498.5M in cash, cash equivalents, investments and restricted cash, compared to $412.4M as of December 31, 2018.

  • 02

    May

  • 04

    May

  • 23

    May

ALDR Alder Biopharmaceuticals
$12.23

-0.21 (-1.69%)

11/28/18
PIPR
11/28/18
NO CHANGE
Target $28
PIPR
Overweight
Alder Biopharmaceuticals's epti to benefit from SubQ profile, says Piper Jaffray
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals following her meeting with its CEO Robert Azelby. The analyst says that the discussion of the recent launch of competitor SubQ anti-CGRP mAbs for migraine prevention raised the profile of its eptinezumab, noting that "given epti's rapid onset of effect and deep magnitude of response, the company believes there will be demand" for epti. Brill still sees the program's BLA submission on track for Q1 of 2019 with the potential launch coming in Q1 of 2020.
02/25/19
PIPR
02/25/19
NO CHANGE
Target $28
PIPR
Overweight
Piper Jaffray maintains positive view of Alder Biopharmaceuticals' eptinezumab
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals after its Q4 results and update on eptinezumab this evening. The analyst maintains a positive view on the program and contends that "eptinezumab is the best suited agent for the most debilitated migraine patients", adding that the company could generate peak revenues of over $1B if it were to capture just the severe subset of patients.
04/04/19
PIPR
04/04/19
NO CHANGE
PIPR
Overweight
Piper Jaffray stays Overweight on Alder Biopharma, Amgen after Novartis filing
Piper Jaffray analyst Christopher Raymond maintains his Overweight rating on Alder Biopharma (ALDR) and Amgen (AMGN) after the filing by Novartis (NVS) alleging legal dispute with the latter about their migraine collaboration. The analyst says that Novartis tried to beat Amgen to the punch after entering agreement with Alder to manufacture eptinezumab, which prompted Amgen to terminate their commercialization agreement. Raymond adds that a resolution of this dispute could take a year or more but believes that investors may conclude that the spat reflects the value of anti-CGRP assets.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."

TODAY'S FREE FLY STORIES

PMBC

Pacific Mercantile Bancorp

$8.19

-0.08 (-0.97%)

08:07
07/22/19
07/22
08:07
07/22/19
08:07
Earnings
Pacific Mercantile Bancorp reports Q2 EPS 12c, two est. 13c »

Reports Q2 CET1 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$44.40

-0.03 (-0.07%)

, BOX

Box

$16.75

-0.23 (-1.35%)

08:06
07/22/19
07/22
08:06
07/22/19
08:06
Hot Stocks
Morgan Stanley launches document sharing portal powered by Box »

Morgan Stanley (MS)…

MS

Morgan Stanley

$44.40

-0.03 (-0.07%)

BOX

Box

$16.75

-0.23 (-1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 19

    Sep

BIOC

Biocept

$1.02

-0.01 (-0.97%)

08:06
07/22/19
07/22
08:06
07/22/19
08:06
Hot Stocks
Biocept announces Laboratory Services Provider Agreement with BeaconLBS »

Biocept announces that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSRR

Sierra Bancorp

$25.86

0.15 (0.58%)

08:05
07/22/19
07/22
08:05
07/22/19
08:05
Earnings
Sierra Bancorp reports Q2 EPS 57c, consensus 55c »

Reports Q2 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOTH

Hoth Therapeutics

$4.50

-0.2 (-4.26%)

08:04
07/22/19
07/22
08:04
07/22/19
08:04
Hot Stocks
Hoth announces results from pilot study of BioLexa platform application »

Hoth Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRRX

Durect

$0.72

0.0503 (7.47%)

, GILD

Gilead

$65.04

-2.18 (-3.24%)

08:03
07/22/19
07/22
08:03
07/22/19
08:03
Hot Stocks
Durect, Gilead enter license agreement for long-acting injectable HIV product »

Durect (DRRX) announced…

DRRX

Durect

$0.72

0.0503 (7.47%)

GILD

Gilead

$65.04

-2.18 (-3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 30

    Jul

  • 07

    Aug

  • 09

    Sep

PETS

PetMed Express

$16.26

-0.015 (-0.09%)

08:03
07/22/19
07/22
08:03
07/22/19
08:03
Earnings
PetMed Express reports Q1 EPS 26c, consensus 46c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 26

    Jul

FB

Facebook

$198.38

-2.4 (-1.20%)

08:02
07/22/19
07/22
08:02
07/22/19
08:02
Recommendations
Facebook analyst commentary  »

Facebook's resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

MRNS

Marinus Pharmaceuticals

$3.88

-0.065 (-1.65%)

08:02
07/22/19
07/22
08:02
07/22/19
08:02
Recommendations
Marinus Pharmaceuticals analyst commentary  »

Marinus could rally up to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMU

JMU

$1.28

(0.00%)

08:01
07/22/19
07/22
08:01
07/22/19
08:01
Hot Stocks
JMU divests food supply chain business »

JMU announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$137.29

-2 (-1.44%)

07:57
07/22/19
07/22
07:57
07/22/19
07:57
Hot Stocks
Equifax announces $671M settlement related to cybersecurity incident »

Equifax announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 06

    Aug

  • 12

    Aug

  • 13

    Nov

GES

Guess

$16.64

0.235 (1.43%)

07:57
07/22/19
07/22
07:57
07/22/19
07:57
Recommendations
Guess analyst commentary at Jefferies »

Guess near-term results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTS

Zoetis

$114.05

-0.91 (-0.79%)

07:56
07/22/19
07/22
07:56
07/22/19
07:56
Recommendations
Zoetis analyst commentary at Stifel »

Zoetis price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

MCFT

MasterCraft Boat Holdings

$18.72

-0.48 (-2.50%)

, HZO

MarineMax

$16.59

-0.025 (-0.15%)

07:56
07/22/19
07/22
07:56
07/22/19
07:56
Downgrade
MasterCraft Boat Holdings, MarineMax, Malibu Boats rating change  »

MasterCraft Boat Holdings…

MCFT

MasterCraft Boat Holdings

$18.72

-0.48 (-2.50%)

HZO

MarineMax

$16.59

-0.025 (-0.15%)

MBUU

Malibu Boats

$35.20

-1.07 (-2.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MBUU

Malibu Boats

$35.20

-1.07 (-2.95%)

, HZO

MarineMax

$16.59

-0.025 (-0.15%)

07:54
07/22/19
07/22
07:54
07/22/19
07:54
Downgrade
Malibu Boats, MarineMax, MasterCraft Boat Holdings rating change  »

Malibu Boats downgraded…

MBUU

Malibu Boats

$35.20

-1.07 (-2.95%)

HZO

MarineMax

$16.59

-0.025 (-0.15%)

MCFT

MasterCraft Boat Holdings

$18.72

-0.48 (-2.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

BBIO

BridgeBio

$27.51

1.55 (5.97%)

07:53
07/22/19
07/22
07:53
07/22/19
07:53
Initiation
BridgeBio initiated  »

BridgeBio initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZO

MarineMax

, MBUU

Malibu Boats

$35.20

-1.07 (-2.95%)

07:53
07/22/19
07/22
07:53
07/22/19
07:53
Downgrade
MarineMax, Malibu Boats, MasterCraft Boat Holdings rating change  »

MarineMax downgraded to…

HZO

MarineMax

MBUU

Malibu Boats

$35.20

-1.07 (-2.95%)

MCFT

MasterCraft Boat Holdings

$18.72

-0.48 (-2.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

HON

Honeywell

$172.94

-0.92 (-0.53%)

07:53
07/22/19
07/22
07:53
07/22/19
07:53
Recommendations
Honeywell analyst commentary at Argus »

Momentum of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 06

    Aug

TBIO

Translate Bio

$9.35

-0.3 (-3.11%)

07:51
07/22/19
07/22
07:51
07/22/19
07:51
Initiation
Translate Bio initiated  »

Translate Bio initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MORF

Morphic Holding

07:50
07/22/19
07/22
07:50
07/22/19
07:50
Initiation
Morphic Holding initiated  »

Morphic Holding initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLMD

Galmed

$6.27

-0.11 (-1.72%)

07:50
07/22/19
07/22
07:50
07/22/19
07:50
Initiation
Galmed initiated  »

Galmed initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TERP

TerraForm Power

$14.58

-0.29 (-1.95%)

, ATGFF

AltaGas

$0.00

(0.00%)

07:50
07/22/19
07/22
07:50
07/22/19
07:50
Hot Stocks
TerraForm Power to acquire U.S. distributed generation plarform for $720M »

TerraForm Power (TERP)…

TERP

TerraForm Power

$14.58

-0.29 (-1.95%)

ATGFF

AltaGas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$198.38

-2.4 (-1.20%)

07:50
07/22/19
07/22
07:50
07/22/19
07:50
Recommendations
Facebook analyst commentary at Wedbush »

Facebook might report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

FVCB

FVCBankcorp

$18.28

-0.63 (-3.33%)

07:49
07/22/19
07/22
07:49
07/22/19
07:49
Downgrade
FVCBankcorp rating change at Raymond James »

FVCBankcorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

SKX

Skechers

$39.00

4.25 (12.23%)

07:48
07/22/19
07/22
07:48
07/22/19
07:48
Recommendations
Skechers analyst commentary  »

Skechers' next…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.